Enovis (NYSE:ENOV) Raised to Buy at Wall Street Zen

Enovis (NYSE:ENOV) was upgraded by stock analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued on Monday, Wall Street Zen reports.

Other research analysts have also issued research reports about the company. UBS Group reissued a “buy” rating and set a $51.00 price objective (up from $50.00) on shares of Enovis in a report on Tuesday, July 28th. BTIG Research lowered their price target on Enovis from $40.00 to $36.00 and set a “buy” rating on the stock in a report on Tuesday, September 1st. Citigroup reissued a “market outperform” rating on shares of Enovis in a research report on Wednesday, September 2nd. Evercore set a $32.00 price objective on shares of Enovis in a report on Monday, July 6th. Finally, Citizens Jmp dropped their target price on shares of Enovis from $55.00 to $47.00 and set a “market outperform” rating on the stock in a report on Wednesday, September 2nd. Ten analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Enovis currently has a consensus rating of “Moderate Buy” and a consensus target price of $40.38.

Enovis Stock Up 1.7%

ENOV stock opened at $18.47 on Monday. The firm has a market cap of $1.07 billion, a PE ratio of -0.96 and a beta of 1.31. Enovis has a 1 year low of $17.30 and a 1 year high of $34.28. The company has a fifty day simple moving average of $23.39 and a 200 day simple moving average of $23.57. The company has a current ratio of 1.98, a quick ratio of 1.00 and a debt-to-equity ratio of 0.84.

Enovis (NYSE:ENOV) last posted its earnings results on Thursday, August 6th. The company reported $0.90 EPS for the quarter, topping the consensus estimate of $0.85 by $0.05. Enovis had a negative net margin of 47.96% and a positive return on equity of 12.03%. The firm had revenue of $582.78 million for the quarter, compared to the consensus estimate of $581.84 million. During the same period in the prior year, the business posted $0.79 earnings per share. The business’s quarterly revenue was up 3.2% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Sell-side analysts anticipate that Enovis will post 3.15 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Oliver Engert acquired 2,660 shares of the stock in a transaction dated Friday, September 4th. The shares were acquired at an average cost of $18.80 per share, for a total transaction of $50,008.00. Following the completion of the transaction, the insider owned 63,898 shares in the company, valued at approximately $1,201,282.40. This trade represents a 4.34% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Damien Mcdonald acquired 13,035 shares of the stock in a transaction dated Friday, September 4th. The shares were purchased at an average price of $19.15 per share, for a total transaction of $249,620.25. Following the completion of the transaction, the chief executive officer owned 247,077 shares of the company’s stock, valued at $4,731,524.55. This trade represents a 5.57% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired a total of 23,293 shares of company stock valued at $449,599 in the last quarter. Corporate insiders own 2.90% of the company’s stock.

Institutional Investors Weigh In On Enovis

A number of institutional investors have recently bought and sold shares of the business. Paradigm Capital Management Inc. NY raised its stake in shares of Enovis by 70.2% in the 1st quarter. Paradigm Capital Management Inc. NY now owns 1,776,715 shares of the company’s stock valued at $40,420,000 after buying an additional 732,917 shares in the last quarter. River Road Asset Management LLC lifted its holdings in shares of Enovis by 3.2% during the 4th quarter. River Road Asset Management LLC now owns 1,487,277 shares of the company’s stock worth $39,621,000 after acquiring an additional 46,289 shares during the period. Private Management Group Inc. boosted its position in shares of Enovis by 38.8% during the 2nd quarter. Private Management Group Inc. now owns 1,365,082 shares of the company’s stock valued at $28,257,000 after acquiring an additional 381,705 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its position in shares of Enovis by 38.0% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 1,045,360 shares of the company’s stock valued at $24,430,000 after acquiring an additional 287,687 shares in the last quarter. Finally, Invenomic Capital Management LP increased its stake in Enovis by 6.2% in the fourth quarter. Invenomic Capital Management LP now owns 756,717 shares of the company’s stock valued at $20,159,000 after acquiring an additional 44,048 shares during the period. Institutional investors and hedge funds own 98.45% of the company’s stock.

Enovis Company Profile

Enovis Corporation is a medical technology company that develops, manufactures and distributes products designed to improve patient mobility, support recovery and restore physical function. Its offerings serve orthopedic, sports medicine, rehabilitation and pain-management markets, with products used by healthcare professionals, athletes and patients.

The company’s product portfolio includes orthopedic braces and supports, surgical solutions, cold and compression therapy systems, rehabilitation equipment, physical therapy devices and recovery technologies.